Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
Labcorp acquires MLM Medical Labs to expand global central lab network
Labcorp has acquired MLM Medical Labs, expanding its worldwide central laboratory and biomarker capabilities for clinical studies. MLM is a central …
-
BMS reports positive data from Phase II QUINTESSENTIAL study for r/r MM
Bristol Myers Squibb (BMS) has reported positive top-line results from the registrational Phase II QUINTESSENTIAL trial of arlocabtagene autoleucel (arlo-cel; …
-
FDA grants RMAT designation to RiboX’s RXRG001 for xerostomia
The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to RiboX Therapeutics’ investigational treatment …
-
Rezubio doses first cohort in Phase I trial of inhaled RZ-520
Rezubio has dosed the first cohort of patients in a Phase I trial of RZ-520, an inhaled therapeutic drug for …
-
Novartis India acquires Pfizer brands for $132m
Novartis India has agreed to pay Rs12.5bn ($132m) to acquire the Minipres and Minipress trademarks in India, along with certain …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
Rezubio doses first cohort in Phase I trial of inhaled RZ-520
Rezubio has dosed the first cohort of patients in a Phase I trial of RZ-520, an inhaled therapeutic drug for …
-
Novartis India acquires Pfizer brands for $132m
Novartis India has agreed to pay Rs12.5bn ($132m) to acquire the Minipres and Minipress trademarks in India, along with certain …
-
Philips launches eV14-2v transvaginal transducer
Philips has introduced the eV14-2v transvaginal transducer, an addition to its ultrasound range for obstetrics and gynaecology. The device has received …
-
Novartis’ pelacarsen fails to meet primary endpoint in Lp(a)HORIZON trial
Novartis has reported that the Phase III Lp(a)HORIZON trial of pelacarsen failed to meet its primary endpoint in patients with …
-
FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer
The US Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca's Etcamah (camizestrant), used with a cyclin-dependent kinase …
-
Médunik and Biocodex sign exclusive agreement for Diacomit in Canada
Médunik Canada has entered an exclusive promotional services agreement with Biocodex for Diacomit, a medication approved in Canada as an …
-
Sensorion secures approval for HearConnex Phase I/II study in France
Sensorion has received authorisation from the French National Agency for Medicines and Health Products Safety (ANSM) for its clinical trial application …
-
HR HealthCare rolls out Liv catheter for female self-catheterisation
US-based HR HealthCare has launched the Liv Pre-lubricated Intermittent Catheter, a device developed to support women managing their bladder health …
-
Norroy receives China’s clearance for Phase III study of 177Lu-NYM032
Norroy Bioscience has received approval from the National Medical Products Administration (NMPA) to start a Phase III clinical trial in …
-
Novartis signs $3.2bn drug delivery deal with Alteogen
Novartis has signed an agreement with Alteogen that could be worth up to $3.22bn for the development and commercialisation of …
